Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Souvik Sarkar

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Free Radical Biology & Medicine|June 28, 2021
Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot studyTagreed A Mazi, Kamil Borkowski, John W Newman, et al.
Epigenetics & Chromatin|February 3, 2019
Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancersCharles E Mordaunt, Dorothy A Kieffer, Noreene M Shibata, et al.
Contemporary Clinical Trials|March 27, 2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatmentDonna M Evon, Carol E Golin, Paul Stewart, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2022
Ring-fused 2-pyridones effective against multidrug-resistant Gram-positive pathogens and synergistic with standard-of-care antibioticsTaylor M Nye, Hasan Tükenmez, Pardeep Singh, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
Journal of Hepatology|January 1, 2020
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"Donna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.
Journal of Hepatology|May 17, 2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP studyDonna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Journal of Medicinal Chemistry|July 24, 2023
Design, Synthesis, and Evaluation of Novel Δ<sup>2</sup>-Thiazolino 2-Pyridone Derivatives That Potentiate Isoniazid Activity in an Isoniazid-Resistant <i>Mycobacterium tuberculosis</i> MutantSouvik Sarkar, Anne E Mayer Bridwell, James A D Good, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Free Radical Biology & Medicine|June 28, 2021
Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot studyTagreed A Mazi, Kamil Borkowski, John W Newman, et al.
Epigenetics & Chromatin|February 3, 2019
Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancersCharles E Mordaunt, Dorothy A Kieffer, Noreene M Shibata, et al.
Contemporary Clinical Trials|March 27, 2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatmentDonna M Evon, Carol E Golin, Paul Stewart, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2022
Ring-fused 2-pyridones effective against multidrug-resistant Gram-positive pathogens and synergistic with standard-of-care antibioticsTaylor M Nye, Hasan Tükenmez, Pardeep Singh, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
Journal of Hepatology|January 1, 2020
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"Donna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.
Journal of Hepatology|May 17, 2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP studyDonna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Journal of Medicinal Chemistry|July 24, 2023
Design, Synthesis, and Evaluation of Novel Δ<sup>2</sup>-Thiazolino 2-Pyridone Derivatives That Potentiate Isoniazid Activity in an Isoniazid-Resistant <i>Mycobacterium tuberculosis</i> MutantSouvik Sarkar, Anne E Mayer Bridwell, James A D Good, et al.
Pageof 12